The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung

Jang, Tae Won;Oak, Chul Ho;Chang, Hee Kyung;Suo, Soon Jung;Jung, Mann Hong

  • Published : 20090300
⟨ Previous Next ⟩

Abstract

Background/Aims: Mutations of the epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) are important in the pathogenesis of lung cancer, and recent reports have revealed racial and geographical differences in mutation expression. Methods: This study was conducted to investigate the prevalence of EGFR and KRAS mutations and their correlation with clinical variables in Korean patients with adenocarcinoma of the lung. Formalin-fixed adenocarcinoma specimens from 104 randomly selected patients diagnosed at Kosin University Gospel Hospital from October 1996 to January 2005 were used for the study. Results: We found a high prevalence of EGFR mutations and a low prevalence of KRAS mutations. EGFR mutations were present in 24% (25 of 104) of the samples: one mutation in exon 18, 13 in exon 19, one in exon 20, and 10 in exon 21. The presence of an EGFR mutation was not associated with gender, smoking history, histological grade, age, bronchioalveolar components, or cancer stage in patients with adenocarcinoma of the lung. Conclusions: Mutations of KRAS were present in 9.6% (9 of 94) of the samples: eight in codon 12 and one in codon 13. EGFR mutations were never found in tumors with KRAS mutations, suggesting a mutually exclusive relationship.

Keywords

References

  1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-1934 https://doi.org/10.1126/science.1075762
  2. Arteaga CL. Overview of epidermal growth factor receptorbiology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29(5 Suppl 14):3-9 https://doi.org/10.1016/S0093-7754(02)70085-7
  3. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(18 Suppl):1S-13S https://doi.org/10.1200/JCO.2002.20.1.1
  4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246 https://doi.org/10.1200/JCO.2003.10.038
  5. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated nonsmall-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-2663 https://doi.org/10.1200/JCO.2003.01.039
  6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500 https://doi.org/10.1126/science.1099314
  7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139 https://doi.org/10.1056/NEJMoa040938
  8. Kim YS, Kwon YS, Oh IJ, et al. National survey of lung cancer in Korea, 2005. J Lung Cancer 2007;6:67-73 https://doi.org/10.6058/jlc.2007.6.2.67
  9. Tomizawa Y, Iijima H, Suguna N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005;11:6816-6822 https://doi.org/10.1158/1078-0432.CCR-05-0441
  10. Soung YH, Lee JW, Kim SY, et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005;446:483-488 https://doi.org/10.1007/s00428-005-1254-y
  11. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features of epidermal growth factor receptor mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346 https://doi.org/10.1093/jnci/dji055
  12. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small- cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-2568 https://doi.org/10.1200/JCO.2005.07.799
  13. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-8203 https://doi.org/10.1158/1078-0432.CCR-04-1245
  14. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923 https://doi.org/10.1158/0008-5472.CAN-04-2818
  15. Travis WD, Colby TV, Corrin B. Histological typing of lung and pleural tumours. 3rd ed. New York, Springer-Verlag, 1999
  16. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992;89:4309-4313 https://doi.org/10.1073/pnas.89.10.4309
  17. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992;89:2965-2969 https://doi.org/10.1073/pnas.89.7.2965
  18. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-5730
  19. Minami Y, Tateno H. Associations between cigarette smoking and the risk of four leading cancers in Miyagi Prefecture, Japan: a multi-site case-control study. Cancer Sci 2003;94:540-547 https://doi.org/10.1111/j.1349-7006.2003.tb01480.x
  20. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799-2803
  21. Rodenhuis S, Slebos RJ, Boot AJ, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988;48:5738-5741
  22. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-1043
  23. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52(9 Suppl): 2665S-2669S
  24. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta. 1998;1378:F21-F25 https://doi.org/10.1016/S0304-419X(98)00010-9
  25. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-351 https://doi.org/10.1378/chest.126.2.347
  26. de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2000;119:21-26 https://doi.org/10.1016/S0022-5223(00)70213-3
  27. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 2005;127:768-777 https://doi.org/10.1378/chest.127.3.768